(54 days)
SIMUPLAN Treatment Planning System is intended for use in preparing individual treatment plans for patients undergoing radiation therapy treatment with external beam or brachytherapy. The program output does not directly treat the patient; all information must be confirmed by the physician prior to treatment.
The SIMUPLAN Treatment Planning System is computer based software that runs on a Maclitosh platform. The planning system is comprised of 2 main components; external beam and bracilytheray. The modified device, SIMUPLAN Treatment Planning System version 8.4 software included in this colors and module update only. The external beam software not included in this release. With the brachytherapy module, the patients' image sets (i.e. CT, MR, US or x-ray films), are imported into the system by various methods: DICOM, disk, video, etc. From this data the patients' anatomical structures and tumor site is contoured in order to generate a 3D patient model, or x-ray films are used for 2D reconstruction of the implant area. Following the import of images, the next steps in the process will be to define the treatment machine, reconstruct implant applicators or define template and seed location. From this inframating the user will select the appropriate source (afterloading or seed) to be used for the planning session. Based on the target volume or reconstructed implant, treatment source and prescription dose the treatment plan will be calculated and a dose distribution will be displayed. This treatment plan can be modified by the physician prior to final output and patient treatment. The physician approved treatment plan is then printed out, machine data generated (for remote afterloading) and a hard copy of the isodose distribution is prepared for the patients' permanent record. The patient data is then saved unter a unique file name in the patient database. The program output does not directly treat the patient; all information must be confirmed by the physician prior to treatment.
This 510(k) submission (K093391) for the SIMUPLAN Treatment Planning System is a Special 510(k), indicating modifications to an already cleared device. As such, the submission primarily focuses on demonstrating that the modified device remains substantially equivalent to the predicate device and that the changes do not introduce new questions of safety and effectiveness. It does not present a typical clinical study with acceptance criteria and reported device performance in the way a novel device submission might.
Instead, the "study" referred to here is the analysis of technological considerations and comparison to the predicate device to demonstrate substantial equivalence for the updated software version (8.4) compared to version 7.5 (K030821).
Here's the information based on the provided document, acknowledging the nature of a Special 510(k) for a software update:
1. Table of Acceptance Criteria and Reported Device Performance
The document does not explicitly state acceptance criteria in terms of numerical performance metrics for a clinical study. For a software update in a Special 510(k), acceptance criteria often relate to:
- Verification and validation (V&V) of the software changes: Ensuring the new features work as intended and that existing functionality is not degraded.
- Comparison to predicate device: Demonstrating that the modified device's performance characteristics are substantially equivalent to the predicate device.
- Risk analysis: Confirming that the modifications do not introduce new or increased risks.
Given the document, the primary "performance" reported is related to functional equivalence and the update of specific modules.
| Acceptance Criteria (Implied for Special 510(k) Software Update) | Reported Device Performance (as per submission) |
|---|---|
| Functional Equivalence to predicate device (v7.5) | "SIMUPLAN Treatment Planning System version 8.4 is substantially equivalent to the cleared predicate device, SIMUPLAN Treatment Planning System version 7.5, (#K030821)." |
| Software Module Stability/Integrity after updates | The submission covers "colors and module update only. The external beam software not included in this release." This implies the updated modules function correctly and existing (external beam) functionality is unaffected. |
| Intended Use Maintained | The intended use for preparing individual treatment plans for radiation therapy (external beam or brachytherapy) remains the same. The output still requires physician confirmation before treatment. |
2. Sample Size Used for the Test Set and Data Provenance
- Test Set Sample Size: Not applicable in the context of a typical clinical performance study. For software verification and validation, testing would involve internal test cases and scenarios, but a "test set" from patient data for performance evaluation against a ground truth is not described.
- Data Provenance: Not applicable. The submission refers to image sets (CT, MR, US, x-ray films) that can be imported but does not detail the provenance of data used for internal software testing.
3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications
- Number of Experts: Not applicable. No external expert-adjudicated test set is described.
- Qualifications of Experts: Not applicable.
4. Adjudication Method for the Test Set
- Adjudication Method: Not applicable. No external expert review or adjudication process for a test set is described.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
- MRMC Study: No, a multi-reader multi-case (MRMC) comparative effectiveness study was not conducted or reported in this submission. This type of study is typically done to assess the impact of AI or new technology on human reader performance, which doesn't align with this software update.
6. Standalone (Algorithm Only) Performance Study
- Standalone Study: No, a standalone performance study (algorithm only, without human-in-the-loop) was not conducted or reported in this submission. This device is a treatment planning system, meaning its output is always intended to be confirmed and used by a physician (human-in-the-loop).
7. Type of Ground Truth Used
- Type of Ground Truth: Not applicable for a clinical performance study. For a treatment planning system, accuracy is often validated against physical measurements, phantom studies, and theoretical calculations, or by comparing outputs to clinically accepted standards and predicate devices. The document implies that the "ground truth" for the software's functionality is its ability to accurately process patient image data, reconstruct anatomical structures, define treatment parameters, calculate and display dose distributions consistent with established radiotherapy physics principles, and align with the performance of its predicate.
8. Sample Size for the Training Set
- Training Set Sample Size: Not applicable. As a rule-based or physics-based treatment planning system, it likely does not involve a "training set" in the machine learning sense. The software's algorithms are built upon established physics models and principles, not trained on a dataset of cases.
9. How the Ground Truth for the Training Set Was Established
- Ground Truth for Training Set: Not applicable. See point 8. The "ground truth" for the underlying algorithms would be derived from fundamental physics, dosimetry principles, and clinical standards in radiation oncology rather than a data-driven training process.
{0}------------------------------------------------
Special 510(k) SIMUPLAN Treatment Planning System October 28, 2009
DEC 2 3 2009
Image /page/0/Picture/3 description: The image shows a semi-circular object on top of a rectangular object. The semi-circular object is dark and has a wavy line coming out of the top. There is an arrow pointing down from the semi-circular object to the rectangular object. The rectangular object has dotted lines emanating from the center.
Department of Health and Human Services Center of Device and Radiological Health Office of Device Evaluation Special 510(k) section
SIMUPLAN S.L.
Miguel Hernandez 25 La Eliana 46183 Valencia Spain Phone: (+34) 96-274-3827 Fax: (+34) 96-272-5132
510(K) SUMMARY OF SAFETY AND EFFECTIVENESS INFORMATION as required by section 807.92(c)
Submitter of 510(k):
| Company name: | SIMUPLAN S. L. |
|---|---|
| Registration number: | 3004147829 |
| Address: | Miguel Hernandez 25La Eliana46183 ValenciaSpain |
| Phone: | (+34) 96-274-3827 |
| Fax: | (+34) 96-272-5132 |
| Contact Person: | Conrado Pla Ph.D. |
| Modified Device Name: |
SIMUPLAN Treatment Planning System Trade/Proprietary Name: Common/Usual Name: Radiation Therapy Planning System Classification Name: Accelerator, Linear, Medical, Accessory 21 CFR 892.5050 Class II Classification Product Code: MUJ
Legally Marketed Device(s)
Our device is substantially equivalent to the legally marketed predicate device cited in the table below:
| Manufacturer | Device | 510(k) # |
|---|---|---|
| SIMUPLAN | SIMUPLAN Treatment Planning System, v 7.5 | K030821 |
Description:
The SIMUPLAN Treatment Planning System is computer based software that runs on a Maclitosh platform. The planning system is comprised of 2 main components; external beam and bracilytheray.
Company Confidential
Page 17 of 20
{1}------------------------------------------------
Special 510(k) SIMUPLAN Treatment Planning System October 28, 2009
The modified device, SIMUPLAN Treatment Planning System version 8.4 software included in this colors and module update only. The external beam software not included in this release.
With the brachytherapy module, the patients' image sets (i.e. CT, MR, US or x-ray films), are imported into the system by various methods: DICOM, disk, video, etc. From this data the patients' anatomical structures and tumor site is contoured in order to generate a 3D patient model, or x-ray films are used for 2D reconstruction of the implant area. Following the import of images, the next steps in the process will be to define the treatment machine, reconstruct implant applicators or define template and seed location. From this inframating the user will select the appropriate source (afterloading or seed) to be used for the planning session. Based on the target volume or reconstructed implant, treatment source and prescription dose the treatment plan will be calculated and a dose distribution will be displayed. This treatment plan can be modified by the physician prior to final output and patient treatment. The physician approved treatment plan is then printed out, machine data generated (for remote afterloading) and a hard copy of the isodose distribution is prepared for the patients' permanent record. The patient data is then saved unter a unique file name in the patient database. The program output does not directly treat the patient; all information must be confirmed by the physician prior to treatment.
Intended Use:
SIMUPLAN Treatment Planning System is intended for use in preparing individual treatment plans for patients undergoing radiation therapy treatment with external beam or brachytherapy. The program output does not directly treat the patient; all information must be confirmed by the physician prior to treatment.
Summary of Technological Considerations:
The SIMUPLAN Treatment Planning System version 8.4 is substantially equivalent to the cleared predicate device, SIMUPLAN Treatment Planning System version 7.5, (#K030821).
Comado H
October 23, 2009
Name: Conrado Pla, Ph.D.
Title: President SIMUPLAN S.L.
Date
Company Confidential
{2}------------------------------------------------
Image /page/2/Picture/0 description: The image shows the seal of the U.S. Department of Health & Human Services. The seal features a stylized eagle with its wings spread, facing to the right. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" are arranged in a circular pattern around the eagle.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room - WO66-G609 Silver Spring, MD 20993-0002
DEC 2-3 2009
Simuplan S.L. % Ms. Lu Anne Johnson President CAPAMED, Inc. 1917 29 % Ave RICE LAKE WI 54868
Re: K093391
Trade/Device Name: Simuplan Treatment Planning System Regulation Number: 21 CFR 892.5050 Regulation Name: Medical charged-particle radiation therapy system Regulatory Class: II Product Code: MUJ Dated: December 2, 2009 Received: December 8, 2009
Dear Ms. Johnson:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical
{3}------------------------------------------------
Page 2 -
device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Janine M. Morris
Janine M. Morris Acting Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
Image /page/4/Picture/0 description: The image shows a black and white drawing of a cluster of small, irregularly shaped objects. The objects are scattered across the frame, with a higher concentration in the upper right quadrant. The objects appear to be floating or suspended in space, with no clear indication of a background or supporting structure.
Indications for Use
510(k) Number (if known): K093391
Device Name: SIMUPLAN Treatment Planning System
Indications for Use:
SIMUPLAN Treatment Planning System is intended for use in preparing individual treatment plans for patients undergoing radiation therapy treatment with external beam or brachytherapy. The program output does not directly treat the patient; all information must be confirmed by the physician prior to treatment.
Prescription Use × (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Aorn M. Wh
(Division Sign-Off) Division of Reproductive, Abdominal, and Radiological Devices
510(k) Number_
Company Confidential
Page 3 of 14
§ 892.5050 Medical charged-particle radiation therapy system.
(a)
Identification. A medical charged-particle radiation therapy system is a device that produces by acceleration high energy charged particles (e.g., electrons and protons) intended for use in radiation therapy. This generic type of device may include signal analysis and display equipment, patient and equipment supports, treatment planning computer programs, component parts, and accessories.(b)
Classification. Class II. When intended for use as a quality control system, the film dosimetry system (film scanning system) included as an accessory to the device described in paragraph (a) of this section, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.